Vitrolife starts a company in Japan
Vitrolife establishes a market organization of its own in Japan to strengthen its position in this market, the next largest in the world with regard to the number of infertility treatments.
________________________________________________________________________________________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.
The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 150 employees and the company’s products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are housed in Sweden and USA.
The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail:
. Homepage:
www.vitrolife.com.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.